FDA’s Warning To Lash-Growth Firm Shows Risks In Third-Party Claims
This article was originally published in The Rose Sheet
Executive Summary
An April 18 FDA warning letter to Lifetech Resources LLC demonstrates that cosmetics firms will be held accountable when their websites feature third-party claims and testimonials that cross into drug marketing territory.
You may also be interested in...
‘We Can’t Go Back In Time’: CIR Panel Grapples With Prostaglandins Review Without Animal Test Data
In its safety assessment of two prostaglandin analogues, the Expert Panel for Cosmetic Ingredient Safety determined that certain read-across data from potentially related ingredients were not enough to extrapolate and apply to a prostaglandin review. This and more from the panel's 4-5 December meeting.
CIR Expert Panel’s Prostaglandin Review: Uncertainties Persist Around ‘Eye Makeup’ Ingredients
Cosmetic Ingredient Review’s expert panel issued an insufficient data announcement for two prostaglandin analogs at its June meeting in Washington. The group is reviewing the substances – related to the active ingredient in Allergan’s prescription drug Latisse for eyelash growth – after the US FDA indicated that they could be used lawfully in cosmetic products.
EU's Highest Court Advised Prostaglandin Eyelash Serum Is Not A Medicine Per Se
Just because the use of a substance in a cosmetic product, in this case prostaglandin-derivative methylamide-dihydro-noralfaprostal, has a physiological effect does not mean it's a medicinal product by function, advises the Advocate General of the Court of Justice of the EU in a recent opinion. While the opinion does not bind the CJEU to any decision, it may impact discussions elsewhere with regards to these substances, for example in the US.